Amgen and Allergan plc. today announced the submission of a Marketing Authorization Application to the European Medicines Agency for ABP 215, a biosimilar candidate to Avastin . "The submission of ABP 215 to the EMA is an important milestone as Amgen seeks to expand our oncology portfolio," said Sean E. Harper, M.D., executive vice president o
"Enbrel Biosimilars Clinical Trial Insight" report by PNS Pharma gives comprehensive clinical insight on 36 biosimilars version of Enbrel drug in clinical pipeline. Currently 5 biosimilar version of Enbrel are commercially available in Iran, Mexico, India, UK and Australia. The patent on Enbrel was originally set to expire on October 23, 2012, b
When Andrew Witty became CEO of one of the biggest pharmaceutical firms in the world, GlaxoSmithKline, his industry was so unpopular that campaigners threw red paint at company stands during conferences to represent the blood of those who died because they could not afford medicines. Two years into his tenure, with Big Pharma s reputation in the
The US Food and Drug Administration has granted its final approval for Lupin Ltds armodafinil tablet, which is used for treating sleep disorder. The companys US subsidiary Lupin Pharmaceuticals Inc is expected to commence promotion of this approved product, a generic version of Cephalon Incs Nuvigil tablet, in the US shortly. Nuvigil tablet had US
Momenta Pharmaceuticals, Inc. is a biotechnology company focused on the development of generic versions of complex drugs. Although the drug has been developed and commercialized by both MNTA and Baxter Bioscience, now part of Shire, MNTA is expected to take over M923 in order for Shire to continue its focus on treating patients with rare diseases.
New Psoriasis Study Findings Have Been Reported by Researchers at University of Turin. According to news reporting originating from Turin, Italy, by NewsRx correspondents, research stated, "The infliximab originator's patent recently expired, leading to the production of biosimilar versions of the drug. Our news editors obtained a quote from the re
By a News Reporter-Staff News Editor at Drug Week NEW ORLEANS, Prices for generic drugs to treat heart failure can vary so widely that uninsured patients may not be able to afford them, according to preliminary research presented at the American Heart Association's Scientific Sessions 2016. Researchers surveyed 175 pharmacies in the greater St. L
Sun Pharmaceutical Industries is currently trading at Rs. 718.25, up by 11.95 points or 1.69% from its previous closing of Rs. 706.30 on the BSE. The scrip opened at Rs. 709.80 and has touched a high and low of Rs. 718.50 and Rs. 707.75 respectively. The BSE group `A` stock of face value Rs. 1 has touched a 52 week high of Rs. 898.00 on 23- Feb-201
Altasciences Clinical Research, a leading early phase drug development contract research organization, is delighted to have been named Best Contract Research Organization Niche at the 12 th Annual Scrip Awards held November 30 th in London. We continuously innovate to meet the evolving and increasingly complex needs of our clients, while m
Dec. 01 Lupin Pharmaceuticals Inc., the Baltimore- based subsidiary of Indian drug maker Lupin Ltd., has received final regulatory approval for a generic sleep disorder medication. Lupin's Armodafinil is a generic version of Cephalon Inc.' s Nuvigil, used to treat narcolepsy, sleep apnea and shift work disorder among adults. The final regulatory
Release date- 30112016- Pfizer Inc. today announced that the pivotal REFLECTIONS B3271002 study, a comparative safety and efficacy study of PF-05280014 versus Herceptin, met its primary endpoint. PF-05280014 is being developed by Pfizer as a potential biosimilar to Herceptin. 'As the leading global biosimilars company, we are committed to advancing
Equities in today's lineup are: Mylan N.V., Horizon Pharma PLC, Allergan PLC, and Catalent Inc.. Shares in Hertfordshire, the UK- based Mylan N.V. ended Wednesday's session at $36.61, rising 1.53% from the last trading session. On November 18 th, 2016, research firm Mizuho reiterated its' Buy' rating on the Company's stock with a decrease of the ta
Vensun Pharmaceuticals, Inc., a privately held generic pharmaceuticals company, today announced the completion of $22.5 million Series C preferred financing with a consortium of investors led by Perceptive Advisors, LLC. Deerfield Management Company, L.P. also joins Perceptive Advisors as a new investor in the Company. Joseph Edelman, Founder and C
By a News Reporter-Staff News Editor at Biotech Week Amgen and Allergan plc. announced the submission of a Biologics License Application to the U.S. Food and Drug Administration for ABP 215, a biosimilar candidate to Avastin. ABP 215 is the most advanced of the four oncology biosimilar medicines that Amgen and Allergan are collaborating on.
Argentum Pharmaceuticals LLC, a generic pharmaceutical company, announced today that it has reached a settlement with Alcon Research, Ltd., related to Argentum's generic version of PAZEO . Under the terms of the settlement agreement, Alcon has granted Argentum a license to its U.S. patent covering PAZEO for a generic version of PAZEO .
Nov. 30 Lupin Pharmaceuticals Inc., the Baltimore- based subsidiary of Indian drug maker Lupin Ltd., has received final regulatory approval for a generic sleep disorder medication. Lupin's Armodafini is a generic version of Cephalon Inc.' s Nuvigil, used to treat narcolepsy, sleep apnea and shift work disorder among adults. The final regulatory a
DGAP-News: Formycon AG/ Key word: Study/Miscellaneous Formycon AG: Focus magazine lists Formycon as growth champion 2017 30.11. 2016/ 07:30 The issuer is solely responsible for the content of this announcement.- Press Release// November 30, 2016 Focus magazine lists Formycon
By a News Reporter-Staff News Editor at Biotech Week Eagle Pharmaceuticals announced that it has signed a definitive agreement to acquire Arsia Therapeutics, an early-stage biotechnology firm with proprietary viscosity-reducing technology and formulation know-how. The acquisition will mark Eagle's entry into biologics, the fastest growing sector.
PUNE, India, Nov. 30, 2016/ PRNewswire-iReach/ The report entitled "Global Biosimilar Market: Size, Trends& Forecasts", provides an analysis of global biosimilar market in terms of value. The report also provides a brief analysis of the global biologics market by value and market share by products. Four major biologics namely Humira, Enbrel, Remi
"Humira Biosimilars Clinical Trial Insight" report by PNS Pharma gives comprehensive clinical insight on 33 biosimilars version of Humira drug in clinical pipeline. More than 10 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. The patent protection assigned to Humira will expire in 201
NEW DELHI- Lupin Limited announced that its US subsidiary Lupin Pharmaceuticals Inc. has received final approval for its Armodafinil Tablets 50 mg, 150 mg, 200 mg and 250 mg from the United States Food and Drug Administration to market a generic version of Cephalon, Inc.' s Nuvigil Tablets 50 mg, 150 mg, 200 mg and 250 mg. Lupin's Armodafinil Ta
Pharmaceutical firm Natco Pharma of Hyderabad has got approval from the US Food and Drug Administration to sell its generic version of armodafinil tablets 50 mg, 150 mg, and 250 mg in the US market. Armodafinil tablets are used as wakefulness promoting agents. The drug is used to treat excessive daytime sleepiness associated with narcolepsy, shift
Natco Pharma Limited announced final approval of Abbreviated New Drug Application (ANDA) containing a paragraph IV certification filed with the US Food and Drug Administration (FDA) for generic version of Armodafinil Tablets, 50 mg, 150 mg, and 250 mg.
PCI Synthesis, Inc., a drug substance Contract Manufacturing Organization of new chemical entities and generic active pharmaceutical ingredients, announced that it won the 2016 Healthcare and Pharmaceutical Award for "Best NCE Manufacturer". Conducted by Global Health& Pharma, a global information sharing platform& a multi-disciplinary community of
Pfizer Inc. today announced that the pivotal REFLECTIONS B3271002 study, a comparative safety and efficacy study of PF-05280014 versus Herceptin , met its primary endpoint. PF-05280014 is being developed by Pfizer as a potential biosimilar to Herceptin. As the leading global biosimilars company, we are committed to advancing our robust pipelin